Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy
Avia Wilkerson1, Julian Kim2, Alex Y Huang3
1School of Medicine, Case Western Reserve University, Cleveland, OH, 44106, United States.
Current Topics in Medicinal Chemistry
|November 24, 2016
Summary
Myeloid-derived suppressor cells (MDSCs) hinder anti-cancer immunity. Nanoparticle strategies targeting these cells show promise for improving cancer immunotherapy and patient survival.
Area of Science:
- Immunology
- Oncology
- Nanomedicine
Background:
- Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells that accumulate in cancer.
- MDSCs suppress T cell and NK cell activity, promoting immune evasion and cancer progression.
- High MDSC levels correlate with poor prognosis in various cancers.
Purpose of the Study:
- To review MDSC functions in cancer progression.
- To discuss nanoparticle-based strategies for targeting MDSCs.
- To highlight theranostic innovations for cancer treatment.
Main Methods:
- Review of current literature on MDSC biology and function.
- Analysis of nanoparticle-based approaches for MDSC targeting.
- Discussion of theranostic applications in cancer immunotherapy.
Main Results:
- MDSCs play a critical role in tumor immune escape and metastasis.
- Nanoparticle systems offer a promising platform for MDSC antagonism.
- Targeting MDSCs can potentially improve cancer staging and therapeutic outcomes.
Conclusions:
- MDSCs are key regulators of the tumor immune microenvironment.
- Nanoparticle-mediated targeting of MDSCs represents a viable immunotherapeutic strategy.
- Multifunctional nanoparticles hold potential for improved cancer theranostics and patient survival.
